Back

Single-cell spatial multiomics identifies POSTN+ CAFs mediating chemoradiotherapy resistance in rectal cancer

Sakai, S. A.; Okumura, M.; Morinaga, Y.; Kato, K.; Kojima, M.; Hofmann, F.; Reichholf, B.; Garcia, P. V.; Nakamura, Y.; Sakashita, S.; Nakamura, M.; Hojo, H.; Tsukada, Y.; Ito, M.; Shitara, K.; Bando, H.; Kojima, T.; Zenkoh, J.; Tatekawa, S.; Katsuki, S.; Ogawa, K.; Takahashi, Y.; Suzuki, A.; Suzuki, Y.; Tsuchihara, K.; Gremel, G.; Yamashita, R.; Kageyama, S.-I.

2026-05-05 cancer biology
10.64898/2026.04.30.721803 bioRxiv
Show abstract

Neoadjuvant chemoradiotherapy (CRT) is standard for locally advanced rectal cancer (LARC), yet many patients retain residual disease. To resolve CRT-associated remodeling of the tumor microenvironment, we generated a multimodal spatial atlas from serial sections of paired pretreatment and post-treatment specimens from 24 patients using Xenium single-cell spatial transcriptomics and PhenoCycler multiplex proteomics, profiling 2.8 million cells; matched Visium HD datasets were generated on adjacent serial sections. Resistance was most strongly associated with fibroblast and myeloid programs adjacent to residual tumor. We identify a periostin (POSTN)-expressing CAF subset selectively enriched around residual tumor cells in non-responders, displaying a myofibroblastic phenotype and activating extracellular matrix remodeling, noncanonical WNT signaling, and immunosuppressive pathways. Tumor cells neighboring POSTN+ CAFs show consistent epithelial-mesenchymal transition signatures. Together, this atlas enables interrogation of CRT-induced spatial remodeling and nominates POSTN+ CAFs as key mediators and targets of CRT resistance, with direct relevance to CRT-based combination strategies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 13%
12.6%
2
Nature Cancer
35 papers in training set
Top 0.1%
9.1%
3
Cancer Discovery
61 papers in training set
Top 0.1%
9.1%
4
Nature
575 papers in training set
Top 4%
6.8%
5
Cancer Cell
38 papers in training set
Top 0.3%
4.8%
6
Nature Cell Biology
99 papers in training set
Top 1%
4.3%
7
Cell
370 papers in training set
Top 5%
4.3%
50% of probability mass above
8
Cell Reports Medicine
140 papers in training set
Top 1%
3.9%
9
Cell Reports
1338 papers in training set
Top 13%
3.9%
10
Nature Genetics
240 papers in training set
Top 2%
3.9%
11
Cancer Research
116 papers in training set
Top 0.8%
3.6%
12
Science
429 papers in training set
Top 12%
2.1%
13
Genome Medicine
154 papers in training set
Top 4%
2.1%
14
Nature Medicine
117 papers in training set
Top 2%
1.9%
15
Cell Stem Cell
57 papers in training set
Top 1%
1.7%
16
Science Advances
1098 papers in training set
Top 18%
1.7%
17
Molecular Cell
308 papers in training set
Top 7%
1.7%
18
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.6%
19
Science Translational Medicine
111 papers in training set
Top 4%
1.3%
20
Cell Genomics
162 papers in training set
Top 5%
1.2%
21
Developmental Cell
168 papers in training set
Top 10%
1.2%
22
Advanced Science
249 papers in training set
Top 15%
1.1%
23
Cell Metabolism
49 papers in training set
Top 2%
0.9%
24
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
25
Oncogene
76 papers in training set
Top 2%
0.8%
26
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
27
Cell Systems
167 papers in training set
Top 14%
0.6%
28
Genome Biology
555 papers in training set
Top 9%
0.6%
29
Immunity
58 papers in training set
Top 5%
0.6%
30
Nature Biotechnology
147 papers in training set
Top 9%
0.6%